# Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

> **NCT01972152** · PHASE2 · COMPLETED · sponsor: **Xeris Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Hypoglycemia

## Interventions

- **DRUG:** G-Pen(TM) 1 mg
- **DRUG:** Lilly Glucagon(TM) 1 mg
- **DRUG:** G-Pen(TM) 0.5 mg

## Key facts

- **NCT ID:** NCT01972152
- **Lead sponsor:** Xeris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-02-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01972152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01972152, "Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01972152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*